Physician profile
Mitchell C Rosenberg
NPI 1477504017
$18,952.17
in general payments reported to CMS, 2019-2025
35 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,318 · 2020: $1,453 · 2021: $1,395 · 2022: $1,077 · 2023: $1,284 · 2024: $10K · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,081 · Food and Beverage: $4,588 · Travel and Lodging: $32.16 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,080.75 |
| Food and Beverage | $4,587.64 |
| Travel and Lodging | $32.16 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $8,518.57 | 2023-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $1,573.33 | 2019-2024 | Xarelto |
| Amgen INC. | $1,207.60 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,162.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $812.88 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $737.73 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $736.50 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $540.99 | 2021-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $375.23 | 2022-2024 | Barostim Neo System |
| Abbott Laboratories | $352.67 | 2019-2025 | Aveir, Perclose Prostyle |
| Amarin Pharma, INC. | $343.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $322.67 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $279.17 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $278.18 | 2019-2025 | Watchman Flx, Varithena Administration Pack |
| Sanofi-Aventis U.S. LLC | $233.55 | 2019-2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.